Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
J Extra Corpor Technol ; 54(4): 338-342, 2022 Dec.
Article in English | MEDLINE | ID: mdl-36742021

ABSTRACT

Alagille syndrome is an autosomal dominant disorder that is caused by heterozygous mutation of JAG1 or NOTCH2 gene that impacts several multisystem organs including but may not be limited to the liver, heart, musculoskeletal, skin, and the eyes. The most common congenital heart defect associated with Alagille syndrome is multilevel right ventricular outflow tract obstruction with multiple central and peripheral branch pulmonary arterial stenoses occurring in up to two-thirds of these patients. We report two cases of Alagille syndrome who underwent extensive pulmonary arterial branch rehabilitation and experienced unusual oxygenator failure during cardiopulmonary bypass (CPB). We present lessons learned from these two cases and the changes that we implemented in our practice that facilitated smooth conduct of CPB in other cases that we performed subsequently.


Subject(s)
Alagille Syndrome , Heart Defects, Congenital , Hypertension, Pulmonary , Humans , Alagille Syndrome/complications , Alagille Syndrome/surgery , Alagille Syndrome/genetics , Cardiopulmonary Bypass/adverse effects , Hypertension, Pulmonary/complications , Oxygenators/adverse effects
2.
Pediatr Allergy Immunol ; 25(2): 180-6, 2014 Mar.
Article in English | MEDLINE | ID: mdl-24520985

ABSTRACT

BACKGROUND: Infants born prematurely are often treated with supplemental oxygen, which can increase their risk for airway hyper-responsiveness (AHR), asthma, reduced lung function, and altered responses to respiratory viral infections later in childhood. Likewise, exposure of newborn mice to hyperoxia alters baseline pulmonary mechanics and the host response to influenza A virus infection in adult mice. Here, we use this mouse model to test the hypothesis that neonatal hyperoxia also promotes AHR and exacerbated allergen-induced symptoms in adult mice. METHODS: Baseline lung mechanics and AHR measured by methacholine provocation were assessed in adult male and female mice exposed to room air or 100% oxygen (hyperoxia) between post-natal days 0-4. AHR and lung inflammation were evaluated after adult female mice were sensitized with ovalbumin (OVA) plus alum and challenged with aerosolized OVA. RESULTS: Baseline lung compliance increased and resistance decreased in adult female, but not male, mice exposed to neonatal hyperoxia compared with siblings exposed to room air. Neonatal hyperoxia significantly enhanced methacholine-induced AHR in female mice, but did not affect allergen-induced AHR to methacholine or lung inflammation. CONCLUSION: Increased incidence of AHR and asthma is reported in children born prematurely and exposed to supplemental oxygen. Our findings in adult female mice exposed to hyperoxia as neonates suggest that this AHR reported in children born prematurely may reflect non-atopic wheezing due to intrinsic structural changes in airway development.


Subject(s)
Bronchial Hyperreactivity/physiopathology , Bronchoconstriction , Hyperoxia/physiopathology , Lung/physiopathology , Pneumonia/physiopathology , Age Factors , Airway Resistance , Animals , Animals, Newborn , Bronchial Hyperreactivity/chemically induced , Bronchial Hyperreactivity/diagnosis , Bronchial Provocation Tests , Bronchoconstrictor Agents/pharmacology , Disease Models, Animal , Female , Hyperoxia/complications , Hyperoxia/diagnosis , Lung Compliance , Male , Methacholine Chloride , Mice, Inbred C57BL , Molecular Sequence Data , Ovalbumin , Pneumonia/chemically induced , Pneumonia/diagnosis , Risk Factors , Sex Factors
3.
Mol Immunol ; 56(1-2): 91-7, 2013 Nov.
Article in English | MEDLINE | ID: mdl-23685261

ABSTRACT

Preeclampsia is a major obstetric problem defined by new-onset hypertension and proteinuria associated with compromised placental perfusion. Although activation of the complement system is increased in preeclampsia compared to normal pregnancy, it remains unclear whether excess complement activation is a cause or consequence of placental ischemia. Therefore, we hypothesized that complement activation is critical for placental ischemia-induced hypertension. We employed the reduced utero-placental perfusion pressure (RUPP) model of placental ischemia in the rat to induce hypertension in the third trimester and evaluated the effect of inhibiting complement activation with a soluble recombinant form of an endogenous complement regulator, human complement receptor 1 (sCR1; CDX-1135). On day 14 of a 21-day gestation, rats received either RUPP or Sham surgery and 15 mg/kg/day sCR1 or saline intravenously on days 14-18. Circulating complement component 3 decreased and complement activation product C3a increased in RUPP vs. Sham (p<0.05), indicating complement activation had occurred. Mean arterial pressure (MAP) measured on day 19 increased in RUPP vs. Sham rats (109.8±2.8 mmHg vs. 93.6±1.6 mmHg). Treatment with sCR1 significantly reduced elevated MAP in RUPP rats (98.4±3.6 mmHg, p<0.05) and reduced C3a production. Vascular endothelial growth factor (VEGF) decreased in RUPP compared to Sham rats, and the decrease in VEGF was not affected by sCR1 treatment. Thus, these studies have identified a mechanistic link between complement activation and the pregnancy complication of hypertension apart from free plasma VEGF and have identified complement inhibition as a potential treatment strategy for placental ischemia-induced hypertension in preeclampsia.


Subject(s)
Complement Activation/physiology , Hypertension/physiopathology , Ischemia/physiopathology , Placenta/physiopathology , Animals , Arterial Pressure/drug effects , Carotid Arteries/drug effects , Carotid Arteries/physiopathology , Complement Activation/drug effects , Complement C3/metabolism , Dose-Response Relationship, Drug , Female , Humans , Hypertension/blood , Hypertension/metabolism , In Vitro Techniques , Male , Nitroprusside/pharmacology , Placenta/blood supply , Placenta/metabolism , Pre-Eclampsia/blood , Pre-Eclampsia/metabolism , Pre-Eclampsia/physiopathology , Pregnancy , Rats , Rats, Sprague-Dawley , Receptors, Complement/administration & dosage , Time Factors , Uterus/blood supply , Uterus/metabolism , Uterus/physiopathology , Vascular Endothelial Growth Factor A/blood , Vascular Endothelial Growth Factor A/metabolism , Vascular Endothelial Growth Factor Receptor-1/blood , Vascular Endothelial Growth Factor Receptor-1/metabolism , Vasodilation/drug effects , Vasodilator Agents/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...